AGTR1 Inhibits the Progression of Lung Adenocarcinoma

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.2166033538338
   PubMed Web of Science ®Google Scholar
• Imyanitov EN, Iyevleva AG, Levchenko EV. Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives. Crit Rev Oncol Hematol. 2021;157:103194. doi:10.1016/j.critrevonc.2020.10319433316418
   PubMed Web of Science ®Google Scholar
• de Groot P, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Radiol Clin North Am. 2012;50(5):863–876. doi:10.1016/j.rcl.2012.06.00622974775
   PubMed Web of Science ®Google Scholar
• Tang H, Liao Y, Zhang C, et al. Fulvestrant-mediated inhibition of estrogen receptor signaling slows lung cancer progression. Oncol Res. 2014;22(1):13–20. doi:10.3727/096504014x1407775173031525700354
   PubMed Web of Science ®Google Scholar
• Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. doi:10.1136/bmj.k420930355745
   PubMed Web of Science ®Google Scholar
• Bai Y, Shen W, Zhu M, et al. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer. J Cell Biochem. 2019;120(1):105–114. doi:10.1002/jcb.2713030216488
   PubMed Web of Science ®Google Scholar
• Tang H, Liao Y, Xu L, et al. Estrogen and insulin-like growth factor 1 synergistically promote the development of lung adenocarcinoma in mice. Int J Cancer. 2013;133(10):2473–2482. doi:10.1002/ijc.2826223649836
   PubMed Web of Science ®Google Scholar
• Tang H, Liao Y, Chen G, et al. Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β. Med Oncol. 2012;29(4):2640–2648. doi:10.1007/s12032-012-0198-822427208
   PubMed Web of Science ®Google Scholar
• Bai Y, Shen W, Zhang L, et al. Oestrogen receptor β5 and epidermal growth factor receptor synergistically promote lung cancer progression. Autoimmunity. 2018;51(4):157–165. doi:10.1080/08916934.2018.148682530022688
   PubMed Web of Science ®Google Scholar
• Eckenstaler R, Sandori J, Gekle M, Benndorf RA. Angiotensin II receptor type 1 - An update on structure, expression and pathology. Biochem Pharmacol. 2021;192:114673. doi:10.1016/j.bcp.2021.11467334252409
   PubMed Web of Science ®Google Scholar
• George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nature reviews. Cancer. 2010;10(11):745–759. doi:10.1038/nrc294520966920
   PubMed Web of Science ®Google Scholar
• Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet (London, England). 1998;352(9123):179–184. doi:10.1016/s0140-6736(98)03228-0
   PubMed Web of Science ®Google Scholar
• Catarata MJ, Ribeiro R, Oliveira MJ, Robalo Cordeiro C, Medeiros R. Renin-angiotensin system in lung tumor and microenvironment interactions. Cancers (Basel). 2020;12:6. doi:10.3390/cancers12061457
   Web of Science ®Google Scholar
• Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010;11(7):627–636. doi:10.1016/s1470-2045(10)70106-620542468
   PubMed Web of Science ®Google Scholar
• Ma Y, Xia Z, Ye C, et al. AGTR1 promotes lymph node metastasis in breast cancer by upregulating CXCR4/SDF-1α and inducing cell migration and invasion. Aging (Albany NY). 2019;11(12):3969–3992. doi:10.18632/aging.10203231219799
   PubMedGoogle Scholar
• Oh E, Kim JY, Cho Y, et al. Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis. Biochim Biophys Acta. 2016;1863(6Pt A):1071–1081. doi:10.1016/j.bbamcr.2016.03.01026975580
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10. doi:10.1158/0008-5472.can-17-030729092952
   PubMed Web of Science ®Google Scholar
• Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560. doi:10.1093/nar/gkz43031114875
   PubMed Web of Science ®Google Scholar
• Györffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi:10.1007/s10549-009-0674-920020197
   PubMed Web of Science ®Google Scholar
• Mizuno H, Kitada K, Nakai K, Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2009;2:18. doi:10.1186/1755-8794-2-1819393097
   PubMed Web of Science ®Google Scholar
• Rosenbloom KR, Armstrong J, Barber GP, et al. The UCSC genome browser database: 2015 update. Nucleic Acids Res. 2015;43(Databaseissue):D670–D681. doi:10.1093/nar/gku117725428374
   PubMed Web of Science ®Google Scholar
• Miao YR, Zhang Q, Lei Q, et al. ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Advan Sci. 2020;7(7):1902880. doi:10.1002/advs.201902880
   Web of Science ®Google Scholar
• Tang H, Bai Y, Xiong L, et al. Interaction of estrogen receptor β5 and interleukin 6 receptor in the progression of non-small cell lung cancer. J Cell Biochem. 2018. doi:10.1002/jcb.27510
   Web of Science ®Google Scholar
• Vinson GP, Barker S, Puddefoot JR. The renin-angiotensin system in the breast and breast cancer. Endocr Relat Cancer. 2012;19(1):R1–R19. doi:10.1530/erc-11-033522180497
   PubMed Web of Science ®Google Scholar
• Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Re. 2005;11(7):2686–2694. doi:10.1158/1078-0432.ccr-04-1946
   PubMed Web of Science ®Google Scholar
• Kinoshita J, Fushida S, Harada S, et al. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int J Oncol. 2009;34(6):1573–1582. doi:10.3892/ijo_0000028719424575
   PubMed Web of Science ®Google Scholar
• Salgia R, Stille JR, Weaver RW, et al. A randomized Phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer. Lung Cancer. 2017;105:7–13. doi:10.1016/j.lungcan.2016.12.02028236984
   PubMed Web of Science ®Google Scholar
• Macaluso M, Montanari M, Giordano A. The regulation of ER-alpha transcription by pRb2/p130 in breast cancer. Ann Oncol. 2005;16 Suppl 4:iv20–iv22. doi:10.1093/annonc/mdi90315923424
   PubMed Web of Science ®Google Scholar
• Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized Phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable Stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33(24):2660–2666. doi:10.1200/jco.2014.60.013026150444
   PubMed Web of Science ®Google Scholar
• Mirandola L, Wade R, Verma R, et al. Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium. Int Rev Immunol. 2015;34(2):134–142. doi:10.3109/08830185.2015.101841725901858
   PubMed Web of Science ®Google Scholar
• Bang YJ, Golan T, Dahan L, et al. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia/b study (JVDJ). Eur j Cancer. 2020;137:272–284. doi:10.1016/j.ejca.2020.06.00732827847
   PubMed Web of Science ®Google Scholar
• Wennhold K, Shimabukuro-Vornhagen A, von Bergwelt-baildon M. B cell-based cancer immunotherapy. Transfus Med Hemother. 2019;46(1):36–46. doi:10.1159/00049616631244580
   PubMed Web of Science ®Google Scholar
• Stankovic B, Bjørhovde HAK, Skarshaug R, et al. Immune cell composition in human non-small cell lung cancer. Front Immunol. 2018;9:3101. doi:10.3389/fimmu.2018.0310130774636
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74–e80. doi:10.1182/blood-2010-02-25855820628149
   PubMed Web of Science ®Google Scholar
• Movahedi K, Laoui D, Gysemans C, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70(14):5728–5739. doi:10.1158/0008-5472.can-09-467220570887
   PubMed Web of Science ®Google Scholar
• Yeap WH, Wong KL, Shimasaki N, et al. CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes. Sci Rep. 2016;6:34310. doi:10.1038/srep3431027670158
   PubMed Web of Science ®Google Scholar
• Hartwig T, Montinaro A, von Karstedt S, et al. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol Cell. 2017;65(4):730.e5–742.e5. doi:10.1016/j.molcel.2017.01.021
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol. 2012;22(4):275–281. doi:10.1016/j.semcancer.2012.01.01122313874
   PubMed Web of Science ®Google Scholar
• Cheng HW, Chen YF, Wong JM, et al. Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway. J Exp Clin Cancer Res. 2017;36(1):27. doi:10.1186/s13046-017-0495-328173828
   PubMed Web of Science ®Google Scholar
• Xu PZ, Chen ML, Jeon SM, Peng XD, Hay N. The effect Akt2 deletion on tumor development in Pten(±) mice. Oncogene. 2012;31(4):518–526. doi:10.1038/onc.2011.24321743498
   PubMed Web of Science ®Google Scholar
• Saji M, Narahara K, McCarty SK, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene. 2011;30(42):4307–4315. doi:10.1038/onc.2011.13621532616
   PubMed Web of Science ®Google Scholar
• Zhao J, Yang T, Ji J, Zhao F, Li C, Han X. RHPN1-AS1 promotes cell proliferation and migration via miR-665/Akt3 in ovarian cancer. Cancer Gene Ther. 2021;28(1–2):33–41. doi:10.1038/s41417-020-0180-032457485
   PubMed Web of Science ®Google Scholar
• Qi YJ, Zha WJ, Zhang W. MicroRNA-217 alleviates development of non-small cell lung cancer by inhibiting AKT3 via PI3K pathway. Eur Rev Med Pharmacol Sci. 2018;22(18):5972–5979. doi:10.26355/eurrev_201809_1592830280779
   PubMed Web of Science ®Google Scholar
• Sung JS, Park KH, Kim ST, Kim YH. Discovery and evaluation of polymorphisms in the AKT2 and AKT3 promoter regions for risk of Korean lung cancer. Genomics Inform. 2012;10(3):167–174. doi:10.5808/gi.2012.10.3.16723166527
   PubMedGoogle Scholar
• Linnerth-Petrik NM, Santry LA, Petrik JJ, Wootton SK. Opposing functions of Akt isoforms in lung tumor initiation and progression. PLoS One. 2014;9(4):e94595. doi:10.1371/journal.pone.009459524722238
   PubMed Web of Science ®Google Scholar